This is supported by the patient TMA IHC data demonstrating significant ALK protein expression across a diverse group of neuroblastoma tumors, suggesting that the vast majority of patients are above the therapeutic threshold of ALK surface expression and could benefit from an ALK-directed ADC. The gene discussed is ALK; the disease is neuroblastoma.